The effect of the AN69 ST100 versus oXiris<sup>®</sup> membrane on filter life during CRRT for non-anticoagulated liver failure patients.
Issued Date
2023-04-01
Resource Type
ISSN
03913988
eISSN
17246040
Scopus ID
2-s2.0-85150615486
Pubmed ID
36895128
Journal Title
International Journal of Artificial Organs
Volume
46
Issue
4
Start Page
209
End Page
214
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Artificial Organs Vol.46 No.4 (2023) , 209-214
Suggested Citation
Naorungroj T., Baldwin I., Eastwood G., Bellomo R. The effect of the AN69 ST100 versus oXiris<sup>®</sup> membrane on filter life during CRRT for non-anticoagulated liver failure patients.. International Journal of Artificial Organs Vol.46 No.4 (2023) , 209-214. 214. doi:10.1177/03913988231155253 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81700
Title
The effect of the AN69 ST100 versus oXiris<sup>®</sup> membrane on filter life during CRRT for non-anticoagulated liver failure patients.
Author(s)
Other Contributor(s)
Abstract
Backgrounds: In patients with liver failure, continuous renal replacement therapy (CRRT) without anticoagulation may be necessary. A new heparin coated membrane (oXiris®) may prolong circuit life in this setting. Objectives: In liver failure patients not receiving anticoagulation, to compare CRRT circuit life with the oXiris® versus the AN69 ST100 (usual care) membrane. Methods: Randomized single cross-over trial. Results: We studied 20 patients and 39 circuits. Twenty-five treatments used femoral and 14 internal jugular access catheters. Median circuit life was 21 h (IQR: 8.25–35.5) with the AN69 versus 16.0 h (14–25) with the oXiris® membrane (p = 0.36). Median first circuit duration was 14 (11.25–23) h for the AN69 ST100 versus 16 (8 –26) for the oXiris® membrane. There was also no difference between the AN69 ST100 or oXiris® membrane circuits using femoral access at 13 (8 –22.5) versus 15.5 (12.5–21.5) h (p = 0.57) or internal jugular access at 28 (13–47) versus 23 (21–29) h (p = 0.79), respectively. Conclusions: The oXiris® heparin-grafted membrane does not appear to prolong circuit life in liver failure patients receiving CRRT without anticoagulation.